Our Liposomes for RNA Delivery services support biotechnology companies, pharmaceutical research teams, CROs, and academic laboratories that need practical lipid vesicle systems for RNA encapsulation, protection, and intracellular delivery in research and preclinical workflows. Liposome-based RNA formulations can be tailored for mRNA, siRNA, miRNA, sgRNA, circRNA, and other oligonucleotide payloads, but successful performance depends on more than choosing a cationic lipid. Lipid composition, RNA-to-lipid ratio, vesicle size, PEGylation, buffer conditions, purification workflow, and target cell context all influence encapsulation efficiency, colloidal stability, uptake behavior, and downstream assay results.
Our platform integrates formulation design, RNA loading, surface engineering, physicochemical characterization, stability assessment, and delivery-oriented study support to help clients move from payload concept to reproducible liposome data with less rework. Whether you are advancing a broader RNA drug delivery system, comparing bilayer liposomes with a lipid nanoparticle (LNP) for RNA delivery, or pairing formulation work with upstream custom RNA synthesis, we structure each program around real formulation risks, assay compatibility, and decision-ready deliverables.
Low Encapsulation and RNA Loss: RNA loading often drops when lipid composition, mixing sequence, or charge balance is poorly matched to the payload. We help teams optimize complexation strategy, encapsulation workflow, and purification conditions to improve RNA retention without sacrificing particle quality.
Particle Instability and Batch Drift: A formulation that appears acceptable after preparation may change size, leak cargo, or aggregate after buffer exchange, storage, or serum exposure. Our development plans address particle size distribution, polydispersity, zeta potential, and short-term stability so liposome performance is more consistent across studies.
Weak Uptake or Endosomal Release: Good encapsulation does not guarantee intracellular activity. We support selection of cationic, PEGylated, ligand-modified, and fusogenic design features to improve cell interaction and intracellular delivery according to the intended research model.
Payload-Specific Formulation Complexity: mRNA, siRNA, sgRNA, and circular RNA behave differently during formulation because of differences in length, duplex structure, fragility, and purification needs. We adapt formulation logic to the physical characteristics and handling limits of each RNA class.
Unclear Platform Selection: Some projects benefit from bilayer liposomes, while others are better served by ionizable or highly optimized LNP-style systems. Our teams help compare liposome candidates with related options such as an mRNA delivery platform so the formulation route fits the actual project objective instead of following a generic carrier preference.
Our liposome services are built for teams that need more than simple vesicle preparation. We support the technical decisions that determine whether an RNA formulation will be loadable, stable, testable, and worth advancing into broader delivery studies.
By combining lipid selection, RNA handling logic, analytical review, and formulation troubleshooting, we help reduce failed screening cycles and generate clearer data for internal R&D, outsourcing decisions, and follow-on development planning.
The matrix below helps teams compare common liposome design routes for RNA delivery and understand where each format is most useful, where it tends to fail, and what type of development support is usually required.
| Liposome Format | Core Design Logic | Suitable RNA Programs | Main Strengths | Main Risk Areas | Typical Service Focus |
| Classical Cationic Liposome | Positively charged bilayer lipids complex negatively charged RNA through electrostatic interaction | siRNA, miRNA, short oligonucleotides, early screening payloads | Straightforward loading, strong RNA association, useful for rapid feasibility work | Serum sensitivity, aggregation, excess surface charge, variable tolerability in biological models | Lipid screening, charge-ratio optimization, basic uptake and silencing evaluation |
| PEGylated Liposome | Addition of PEG-lipid to improve dispersion behavior and reduce nonspecific interactions | mRNA, siRNA, circRNA, multi-step handling workflows | Better colloidal stability, improved handling, stronger fit for comparative delivery studies | Reduced cell interaction, altered loading efficiency, PEG-density tuning requirements | PEG content optimization, stability studies, particle characterization, formulation balancing |
| Ligand-Targeted Liposome | Surface decoration with peptides, antibodies, glycans, aptamers, or other targeting moieties | Cell-focused delivery studies, receptor-guided uptake exploration, hard-to-transfect systems | More selective cell interaction, better hypothesis testing for targeted delivery concepts | Surface crowding, variable ligand density, added manufacturing and analytical complexity | Conjugation planning, ligand density studies, targeted versus non-targeted comparison work |
| Fusogenic / pH-Responsive Liposome | Membrane-active lipids or pH-sensitive components are used to improve intracellular release | mRNA expression, siRNA knockdown, endosomal escape-limited research models | Better intracellular delivery potential when uptake alone is not the main barrier | Formulation instability, release-control challenges, condition-dependent performance | Membrane-active lipid selection, release profiling, functional screening in cell assays |
| Co-delivery Liposome | Liposome is designed to carry RNA together with helper molecules, dyes, or second payload classes | Combination studies, mechanism work, formulation-enabled assay design | Flexible research design, coordinated payload presentation, useful for complex study goals | Payload competition, loading imbalance, altered particle structure and stability | Multi-payload optimization, ratio control, formulation compatibility assessment |
| Comparative Liposome-LNP Route | Liposome feasibility is evaluated in parallel with ionizable lipid alternatives for better platform selection | Longer RNA payloads, difficult targets, programs with unclear carrier direction | Faster platform decisions, reduced rework, better alignment between payload and carrier system | Broader development scope, more screening work, higher decision complexity at the start | Cross-platform formulation comparison, payload fit analysis, delivery route recommendation |
Strong liposome programs rely on more than formulation preparation alone. The matrix below summarizes the main technical review points used to reduce failure risk, improve reproducibility, and align liposome properties with the biological question being tested.
| Development Category | Core Objective | Typical Readouts | Why It Matters | Stage Alignment |
| Payload Input Review | Match formulation strategy to RNA length, structure, purity, and handling sensitivity | RNA integrity review, concentration check, duplex or transcript status, buffer compatibility | Poor RNA input quality can make a good lipid system appear to fail | Project Initiation |
| Lipid Composition Screening | Identify lipid ratios that support loading, particle formation, and acceptable stability | Formulation matrix review, lipid ratio comparison, vesicle formation success | Composition is the main driver of particle behavior and loading outcome | Discovery |
| Charge Ratio Optimization | Balance RNA association with particle quality and downstream usability | RNA-to-lipid ratio, free RNA fraction, surface charge trend, recovery | Overcharged systems may load well but perform poorly in practical studies | Discovery |
| Particle Quality Assessment | Confirm size control and particle distribution before biological testing | Particle size, PDI, zeta potential, morphology-oriented measurements | Heterogeneous particles create inconsistent uptake and difficult data interpretation | Discovery / Early Development |
| Encapsulation Efficiency Review | Quantify how much RNA is truly associated with usable particles | Encapsulation efficiency, free RNA analysis, post-purification recovery | High apparent loading can be misleading if free or loosely bound RNA remains | Discovery / Early Development |
| Stability and Stress Testing | Evaluate how the formulation behaves during storage, dilution, and handling | Size drift, leakage risk, aggregation, freeze-thaw response, serum exposure | Unstable formulations often fail after transfer into real assay conditions | Early Development |
| Surface Modification Review | Determine whether PEGylation or targeting improves or disrupts the formulation | Particle change after modification, ligand density trend, stability comparison | Surface engineering can improve selectivity but also reduce loading or uptake | Early Development |
| Functional Delivery Evaluation | Confirm that the liposome supports usable intracellular RNA activity | Uptake trend, expression, silencing, reporter response, comparative control analysis | Delivery value must be proven by functional output, not particle metrics alone | Preclinical Research |
| Platform Fit Decision | Decide whether liposomes remain the best option or whether a related lipid platform is needed | Cross-platform comparison, payload fit assessment, manufacturability review | Early redirection can save time when bilayer liposomes are not the best technical fit | Preclinical Planning |
Our workflow is designed for research and preclinical liposome development programs that require clear technical checkpoints from payload review through formulation, characterization, and data handoff.
We confirm RNA type, sequence format, concentration, storage conditions, target cell context, intended readout, and any known formulation constraints. This step defines whether the project is centered on loading feasibility, delivery screening, targeted formulation design, or platform comparison.
A fit-for-purpose liposome design plan is created covering lipid classes, charge strategy, preparation method, purification route, and initial analytical package. We also define whether PEGylation, targeting ligands, or release-enhancing features should be included in the first screen.
Liposomes are prepared using the selected method and combined with the RNA payload under controlled conditions. Mixing sequence, lipid-to-RNA ratio, concentration window, and post-loading cleanup are adjusted to improve particle formation and reduce free RNA carryover.
Key particle and payload attributes are measured, including size, distribution, charge, and encapsulation performance. Where needed, we iterate lipid ratio, PEG level, purification conditions, or processing parameters to improve reproducibility and formulation usability.
Candidate formulations are advanced into handling, storage, serum, or biological performance studies according to project scope. This stage is used to determine whether the formulation remains intact and whether it supports the expected expression, silencing, or uptake trend in the selected model.
We deliver structured formulation data, analytical results, comparison logic, and practical recommendations for next-stage work. Depending on the outcome, the project may advance to expanded liposome screening, targeted modification, broader RNA delivery evaluation, or comparison with other lipid platforms.
Liposome programs succeed when formulation chemistry, RNA handling, and analytical interpretation are developed together rather than as separate outsourced tasks. Our service model is designed to help research teams make better technical decisions earlier and reduce avoidable formulation failure.
Liposomes remain valuable RNA delivery tools across discovery and preclinical research when teams need configurable lipid vesicles, adaptable surface engineering, and practical control over formulation variables. Our services are aligned with the application areas below.
If your team needs a practical partner for RNA liposome formulation, payload loading, characterization, or delivery-focused optimization, we can help you build a study plan around the real technical questions that matter. We work with biotech companies, pharmaceutical research groups, CROs, and academic labs to define liposome composition strategy, improve encapsulation quality, evaluate stability, and generate data that supports better next-step decisions. From early feasibility work to broader preclinical delivery evaluation, our liposome service platform is structured to support demanding RNA programs with clear technical documentation and application-aware development logic. Contact us to discuss your RNA payload, target model, and liposome development requirements.
Liposomal vitamin C is a form of vitamin C in which ascorbic acid (vitamin C) is encapsulated within tiny vesicles composed of phospholipids, resembling cell membranes, known as liposomes. The primary function of liposomal vitamin C is to protect vitamin C from degradation in the digestive system while enhancing its absorption in the body. Through this encapsulation method, vitamin C can be delivered more effectively to specific cells or tissues in the body, thereby increasing its bioavailability and efficacy.
Overall, liposomes have a wide range of applications in both the medical and cosmetic fields. In medicine, they are used to enhance drug delivery, efficacy, and reduce side effects. In cosmetics, liposomes can deliver active ingredients to deeper layers of the skin and improve the efficacy of skin care products. Their unique structure makes them effective carriers of drugs, nutrients and cosmetics.
Liposomal delivery employs lipid-based bubbles known as liposomes to ferry drugs or nutrients. These tiny bubbles encase the active ingredients, facilitating their streamlined transport throughout the body. By utilizing this technique, the potency of the compounds can be enhanced while minimizing potential side effects, as it enables precise delivery to designated cells or tissues.
Liposomal glutathione refers to a form where the antioxidant glutathione is encapsulated within liposomes. Glutathione is a vital antioxidant in the human body, playing important roles in detoxification, immune function, and protecting cells against oxidative stress. Encapsulating glutathione within liposomes can enhance its stability and bioavailability, making it easier for the body to absorb when taken orally. This improved delivery system helps ensure that more glutathione reaches the cells where it's needed, potentially offering greater therapeutic benefits compared to traditional glutathione supplements.
Loading ......
